The FDA granted Breakthrough Therapy designation to Janssen's investigational prophylactic vaccine as a preventive treatment for respiratory syncytial virus-mediated lower respiratory tract disease for adult patients 60 years old and older.
Breakthrough Therapy status granted to Janssen vaccine candidate
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.